<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02819583</url>
  </required_header>
  <id_info>
    <org_study_id>PG-019-001</org_study_id>
    <nct_id>NCT02819583</nct_id>
  </id_info>
  <brief_title>CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma</brief_title>
  <official_title>Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PersonGen BioTherapeutics (Suzhou) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First People's Hospital of Hefei</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hefei Binhu Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anhui Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>PersonGen BioTherapeutics (Suzhou) Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell&#xD;
      immunotherapy in patients with CD19 positive relapsed or refractory Leukemia and Lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I: Adverse events attributed to the administration of the anti-CD19 CAR-T cells</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase II: Objective Response Rate</measure>
    <time_frame>Safety follow-up is 100 days from last CAR-T infusion.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Acute Lymphocytic Leukemia</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Follicular Lymphoma</condition>
  <condition>Mantle Cell Lymphoma</condition>
  <condition>B-cell Prolymphocytic Leukemia</condition>
  <condition>Diffuse Large Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>PCAR-019</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enrolled patients will receive PCAR-019 with a novel specific chimeric antigen receptor targeting CD19 antigen by infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PCAR-019 (anti-CD19 CAR-T cells)</intervention_name>
    <arm_group_label>PCAR-019</arm_group_label>
    <other_name>chimeric antigen receptor T cells with specificity for CD19</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Male and female subjects with CD19+ B cell malignancies in patients with no available&#xD;
        curative treatment options (such as autologous or allogeneic SCT) who have limited&#xD;
        prognosis (several months to &lt; 2 year survival) with currently available therapies will be&#xD;
        enrolled:&#xD;
&#xD;
          1. Eligible diseases: Acute lymphocytic leukemia (ALL), Chronic lymphocytic leukemia&#xD;
             (CLL), Follicular lymphoma, Mantle cell lymphoma, B-cell prolymphocytic leukemia, and&#xD;
             diffuse large cell lymphoma, previously identified as CD19+.&#xD;
&#xD;
          2. Patients 18 years of age or older, and must have a life expectancy &gt; 12 weeks.&#xD;
&#xD;
          3. Eastern cooperative oncology group (ECOG) performance status of 0-2 or karnofsky&#xD;
             performance status (KPS) score is higher than 60.&#xD;
&#xD;
          4. Adequate venous access for apheresis or venous sampling, and no other&#xD;
             contraindications for leukapheresis.&#xD;
&#xD;
          5. Females of child-bearing potential must have a negative pregnancy test and all&#xD;
             subjects must agree to use an effective method of contraception for up to two weeks&#xD;
             after the last infusion of CAR T cells.&#xD;
&#xD;
          6. Adequate bone marrow, liver and renal function as assessed by the following laboratory&#xD;
             requirements: White blood cell count (WBC) ≥ 2500c/ml, Platelets ≥ 50×10^9/L, Hb ≥&#xD;
             9.0g/dL, lymphocyte (LY) ≥ 0.7×10^9/L, LY% ≥ 15%, Alb ≥ 2.8g/dL, serum lipase and&#xD;
             amylase &lt; 1.5×upper limit of normal, serum creatinine ≤ 2.5mg/dL, aspartate&#xD;
             aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5×upper limit of normal,&#xD;
             serum total bilirubin ≤ 2.0mg/dL. These tests must be conducted within 7 days prior to&#xD;
             registration.&#xD;
&#xD;
          7. Ability to give informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The transduction efficiency of the T cells is less than 30% or the amplification of&#xD;
             the T cells via artificial antigen presenting cell (aAPC) stimulation is less than 5&#xD;
             times.&#xD;
&#xD;
          2. Pregnant or nursing women may not participate.&#xD;
&#xD;
          3. Active HIV, hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at the time&#xD;
             of screening.&#xD;
&#xD;
          4. Serious illness or medical condition which would not permit the patient to be managed&#xD;
             according to the protocol, including active uncontrolled infection, major&#xD;
             cardiovascular, coagulation disorders, respiratory or immune system, myocardial&#xD;
             infarction, cardiac arrhythmias, obstructive/restrictive pulmonary disease, or&#xD;
             psychiatric or emotional disorders.&#xD;
&#xD;
          5. History of severe immediate hypersensitivity to any of the agents including&#xD;
             cyclophosphamide, fludarabine, or aldesleukin.&#xD;
&#xD;
          6. Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not&#xD;
             exclusionary.&#xD;
&#xD;
          7. Previously treatment with any gene therapy products.&#xD;
&#xD;
          8. The existence of unstable or active ulcers or gastrointestinal bleeding.&#xD;
&#xD;
          9. Patients need anticoagulant therapy (such as warfarin or heparin).&#xD;
&#xD;
         10. Patients need long-term antiplatelet therapy (aspirin at a dose &gt; 300mg/d; clopidogrel&#xD;
             at a dose &gt; 75mg/d).&#xD;
&#xD;
         11. Patients using fludarabine or cladribine chemotherapy within 3 months prior to&#xD;
             leukapheresis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lin Yang, Ph.D.</last_name>
    <phone>86-512-65922190</phone>
    <email>info@persongen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>PersonGen BioTherapeutics (Suzhou) Co., Ltd.</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215123</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin Yang, Ph.D</last_name>
      <phone>86-512-65922190</phone>
      <email>info@persongen.com</email>
    </contact>
    <investigator>
      <last_name>Xingbing Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xin Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yangyi Bao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lin Yang, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>June 28, 2016</study_first_submitted>
  <study_first_submitted_qc>June 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2016</study_first_posted>
  <last_update_submitted>October 23, 2016</last_update_submitted>
  <last_update_submitted_qc>October 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Prolymphocytic</mesh_term>
    <mesh_term>Leukemia, Prolymphocytic, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

